Tumori Journal · 1990 · 11 citations · 5 references
MedicinePharmacologyPharmacotherapyCancer PharmacologyChemotherapyHematologic OncologyChemotherapy In Hematologic MalignanciesHematologic Malignancy PharmacotherapyHematologic Malignancy TherapyHematologic ToxicityHematologic Toxicity ManagementMultiple MyelomaMultiple Myeloma ChemotherapyMultiple Myeloma TherapyMultiple Myeloma TreatmentMyeloablative ChemotherapyPhase Ii InvestigationRefractory Multiple MyelomaRelapsed Multiple MyelomaStudy Phase
Twenty-one patients with multiple myeloma were treated with idarubicin 45 mg/m2 orally day 1 and prednisone 60 mg/m2 day 1-4 every three weeks. Moderate to severe gastrointestinal and hematopoietic toxicity were observed. Twelve of the twenty-one patients had relapsed on prior treatment. Of these, 2 patients responded. Two patients had primary resistant disease, neither responded. Seven patients had received no prior treatment, three responded. Idarubicin and prednisone have modest activity in refractory myeloma, with short duration of response and severe toxicity.
5
Cancer: Principles and Practice of Oncology
Walter G. Gunn · JAMA · 1986 · 497 citations
Medicine, Oncology, Oncology Nursing +10